Sanofi lifts FY guidance after strong Q2 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
July 26, 2024 7:33 AM EDTArgus analyst Jasper Hellweg raised the price target on Sanofi-Aventis (NASDAQ: SNY) to $60.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "Our rating on Sanofi SA (NGS: SNY), a leading global pharmaceutical company, is BUY. We like Sanofis diverse range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products. The... More
